Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:GNWSFNASDAQ:MYMDNYSE:NAVBOTCMKTS:SZLSF On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGNWSFStageZero Life Sciences$0.02$0.01$0.00▼$1.27$1.51M0.2826,719 shsN/AMYMDMyMD Pharmaceuticals$0.13+3.6%$0.17$1.75▼$63.90$308K2.15134,123 shs5.36 million shsNAVBNavidea Biopharmaceuticals$0.00-50.0%$0.00$0.00▼$0.13$10K1.78,576 shs15,514 shsSZLSFStagezero Life Sciences$0.02$0.01$0.00▼$1.00$2.95M-2.073,617 shsN/A2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGNWSFStageZero Life Sciences-0.12%-0.33%+697.40%+697.40%+1,494.80%MYMDMyMD Pharmaceuticals+3.59%-6.81%-24.64%-63.89%-93.12%NAVBNavidea Biopharmaceuticals0.00%-50.00%-85.71%-75.00%-50.00%SZLSFStagezero Life Sciences+0.09%-16.61%+697.40%+697.40%+1,494.80%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGNWSFStageZero Life SciencesN/AN/AN/AN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASZLSFStagezero Life SciencesN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGNWSFStageZero Life Sciences 0.00N/AN/AN/AMYMDMyMD Pharmaceuticals 0.00N/AN/AN/ANAVBNavidea Biopharmaceuticals 0.00N/AN/AN/ASZLSFStagezero Life Sciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGNWSFStageZero Life Sciences$4.15M0.36N/AN/A($0.02) per share-1.20MYMDMyMD PharmaceuticalsN/AN/AN/AN/A$7.21 per shareN/ANAVBNavidea Biopharmaceuticals$8.13K1.23N/AN/AN/A∞SZLSFStagezero Life Sciences$3.80M0.78N/AN/AN/A∞Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGNWSFStageZero Life Sciences-$6.86M-$0.28N/A∞N/A-200.26%N/A-165.13%N/AMYMDMyMD Pharmaceuticals-$4MN/A0.00∞N/AN/A-179.05%-108.14%N/ANAVBNavidea Biopharmaceuticals-$15.18MN/A0.00∞N/AN/AN/AN/AN/ASZLSFStagezero Life Sciences-$11.41MN/A0.00∞N/AN/AN/AN/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGNWSFStageZero Life SciencesN/AN/AN/AN/AN/AMYMDMyMD PharmaceuticalsN/AN/AN/AN/AN/ANAVBNavidea BiopharmaceuticalsN/AN/AN/AN/AN/ASZLSFStagezero Life SciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGNWSFStageZero Life SciencesN/A1.151.08MYMDMyMD PharmaceuticalsN/A0.620.62NAVBNavidea BiopharmaceuticalsN/AN/AN/ASZLSFStagezero Life SciencesN/A0.020.02Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGNWSFStageZero Life Sciences0.02%MYMDMyMD Pharmaceuticals9.64%NAVBNavidea Biopharmaceuticals0.01%SZLSFStagezero Life SciencesN/AInsider OwnershipCompanyInsider OwnershipGNWSFStageZero Life SciencesN/AMYMDMyMD Pharmaceuticals2.12%NAVBNavidea Biopharmaceuticals43.68%SZLSFStagezero Life Sciences2.54%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGNWSFStageZero Life Sciences8063.00 millionN/ANot OptionableMYMDMyMD Pharmaceuticals62.37 million2.32 millionOptionableNAVBNavidea Biopharmaceuticals10100.08 million56.37 millionOptionableSZLSFStagezero Life Sciences80123.53 million120.40 millionNot OptionableGNWSF, MYMD, SZLSF, and NAVB HeadlinesRecent News About These CompaniesStageZero Life Sciences and ElevationMD Introduce Aristotle and AVRT for the Early Detection of CancerMay 13, 2025 | thenewswire.comTStageZero Life Sciences Ltd. (SZLSF)July 27, 2024 | finance.yahoo.comStageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials Under the Failure To File Cease Trade OrderJuly 9, 2024 | accesswire.comAStageZero Life Sciences Announces Update on Filing of Full Year 2023 Financials under the Failure to File Cease Trade OrderJuly 3, 2024 | accesswire.comAStageZero Life Sciences Ltd: StageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational UpdateMay 17, 2024 | finanznachrichten.deStageZero Life Sciences, Ltd Announces Q1 2024 Financial Results and Operational UpdateMay 17, 2024 | accesswire.comAStageZero Life Sciences Ltd: StageZero Life Sciences Provides an Update on Application for Management Cease Trade OrderApril 5, 2024 | finanznachrichten.deStageZero Life Sciences Provides an Update on Application for Management Cease Trade OrderApril 5, 2024 | accesswire.comAStageZero Life Sciences Announces Delay to Fourth Quarter and Year End 2023 Financial ResultsApril 2, 2024 | accesswire.comAStagezero Life Sciences GAAP EPS of -$0.01, revenue of $0.75MNovember 15, 2023 | seekingalpha.comStageZero Life Sciences, Ltd Announces Results of Resolutions at Annual and Special MeetingJune 7, 2023 | finance.yahoo.comDually-Listed Healthcare Stock Rallies On Q1 ResultsMay 17, 2023 | theglobeandmail.comStageZero to Issue Q1 2023 Financial Results After Market Closes May 15, 2023May 15, 2023 | finance.yahoo.comStagezero Life Sciences GAAP EPS of -$0.09, revenue of $0.7MApril 3, 2023 | msn.comStageZero to Issue Q4 2022 Financial Results on Friday March 31March 30, 2023 | finance.yahoo.comStageZero to Issue Q4 2022 Financial Results and Hold Conference Call on Thursday March 30March 29, 2023 | finance.yahoo.comResults from METRICs Study Informs Expansion of StageZero's New Care Oncology ProtocolFebruary 15, 2023 | finance.yahoo.comStageZero Life Sciences Ltd: StageZero Life Sciences Announces Extension of Warrants Expiring in January 2023January 12, 2023 | finanznachrichten.deStageZero Life Sciences Announces Extension of Warrants Expiring in January 2023January 12, 2023 | finance.yahoo.comStageZero Life Sciences Ltd. (SZLSF) Q3 2022 Earnings Call TranscriptNovember 15, 2022 | seekingalpha.comMedia Sentiment Over TimeGNWSF, MYMD, SZLSF, and NAVB Company DescriptionsStageZero Life Sciences OTCMKTS:GNWSF$0.02 0.00 (0.00%) As of 06/27/2025StageZero Life Sciences Ltd. develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications. Its proprietary platform technology is Sentinel Principle, which identifies novel biomarkers from whole blood. The company's lead product is ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer. It also offers Aristotle, a multi-cancer panel test for simultaneously screening for 10 cancers from a single sample of blood with high sensitivity and specificity for each cancer; and COVID PCR testing and blood test analysis. StageZero Life Sciences Ltd. is headquartered in Richmond Hill, Canada.MyMD Pharmaceuticals NASDAQ:MYMD$0.13 +0.00 (+3.59%) As of 06/27/2025MyMD Pharmaceuticals, Inc., a clinical development stage pharmaceutical company, focuses on developing various therapeutic platforms to treat the aging and age-related and autoimmune diseases, and chronic pain, anxiety, and sleep disorders. The company is developing MYMD-1, a drug platform based on a clinical stage small molecule that regulates the immune system and its pro-inflammatory cytokines to prevent and treat autoimmune diseases and age-related illnesses, and a Phase 2 clinical trial for sarcopenia, multiple sclerosis, diabetes, inflammatory bowel diseases, and rheumatoid arthritis; inflammation related depression and anxiety; and COVID-19-associated depression. It is also developing Supera-CBD, a synthetic analog of cannabidiol for treating epilepsy, pain, and anxiety/depression. The company was founded in 2014 and is headquartered in Baltimore, Maryland.Navidea Biopharmaceuticals NYSE:NAVB$0.0001 0.00 (-50.00%) As of 06/27/2025 03:04 PM EasternNavidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases. It develops NAV3-31, which has completed Phase IIb clinical trials for evaluating imaging repeatability, reproducibility, and stability, as well as the capacity of Tc99m tilmanocept imaging for treatment of anti-tumor necrosis factor alpha therapy in patients with moderate to severe rheumatoid arthritis (RA); NAV3-35 that is in a Phase IIb clinical trial for RA imaging; NAV3-33, which is in Phase III clinical trial for RA; and NAV3-32, which is Phase 2b trial for RA-involved joints. The company is also developing Tc99m tilmanocept for cardiovascular, kaposi's sarcoma, tuberculosis, and other immunotherapeutic applications. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was incorporated in 1983 and is headquartered in Dublin, Ohio.Stagezero Life Sciences OTCMKTS:SZLSF$0.02 0.00 (0.00%) As of 06/27/2025StageZero Life Sciences Ltd., a vertically integrated healthcare company, develops and commercializes proprietary molecular diagnostic tests for the early detection of diseases and personalized health management with a primary focus on cancer-related indications in North America and Western Europe. Its proprietary platform technology is Sentinel Principle, which identifies RNA-based biomarkers from whole blood. The company's lead product is Aristotle, a mRNA-based multi-cancer panel test for for the detection of multiple discrete cancers from a single sample of blood. It also offers ColonSentry, a blood test to determine an individual's current risk for having colorectal cancer; Prostate Health Index, a screening test for prostate cancer; BreastSentry, a test to determine a woman's risk for developing breast cancer; and COVID-19 Tests. The company is based in Richmond Hill, Canada. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Nike Stock: The Mother of All Comebacks Might Have Just Begun EA Just Caught a Monster Upgrade: Bullish Breakout Ahead? Addition by Subtraction: Intel’s New Strategy Energizes Investors Apple: The Mag 7’s Dead Money Stock or AI Cash Cow in the Making? NVIDIA’s Stock Price Hits New Highs: This Is What’s Next Micron: A Hot Buy Heats Up, Fresh All-Time Highs Are Coming Rocket Lab: Europe Comes Calling as Momentum Builds Broadcom’s Big VMware Update: A Threat to Public Cloud Giants? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
